Pandemic Influenza Funding Activities

Visit PandemicFlu.gov for one-stop access to related U.S. Government avian and pandemic flu information. The National Vaccine Program Office is responsible for coordinating the activities of the many federal agencies involved in vaccine and immunization activities.

BARDA is responsible for the tactical and logistical implementation of policies and decisions related to the advanced development, establishment of surge capacity, and acquisition of medical countermeasures such as vaccines and antiviral drugs that may be used to contain, control, and mitigate the mortality and morbidity associated with influenza pandemics in the U.S.. The table below represents the funding activities that BARDA is involved in to improve public health emergency preparedness against pandemic influenza.

For further information on the funding that supports these initiatives as well as other pandemic influenza initiatives that are funded by December 2005 emergency supplemental appropriations bill (PL 109-148) and the June 2006 emergency supplemental appropriations bill (PL 109-234), please see the Pandemic Influenza Preparedness Spending Reports to Congress.

Title	Synopses	RFI#/RFP#	Amendments	Open	Close	Contract Award
Manufacturing Capabilities, Surge Capacity, New Product/New Technology Development for Respiratory Protection Device during Pandemic Influenza Outbreaks		RFI-OPHEMC-07-01
Biological Diagnostics Manufacturing						December 4, 2006 - Contracts awarded to manufacturers totaling $11.4 million: iCepheid($2.4 million), Iquum ($3.8 million), MesoScale ($706,241), Nanogen($4.5 million). (Press Release)
2006 Acquisition of H5N1 Influenza Vaccine						November 17, 2006 - 3 Contracts awarded to manufacturers totaling $199.45 million: sanofi pasteur (3.7 million doses for $117.9 million), Novartis (800,000 doses for $40.95 million), and GlaxoSmithKline (800,000 doses for $40.6 million). (Press Release)
Retrofitting Manufacturing Facilities for Production of Pandemic Influenza Vaccines	DHHS-ORDC-VB-06-07 RFP DHHS-ORDC-VB-06-07	RFI-ORDC-06-02	Amendment 01 Amendment 02 Amendment 03	6/14/06	8/14/06	June 14, 2007 – Contracts awarded to sanofi Pasteur ($77.4 million) and MedImmune ($55.1 million). (Press Release)
Advanced Development of New Antiviral Agents for Influenza	DHHS-ORDC-VB-06-01	RFI-ORDC-06-01 RFP–DHHS-ORDC-VB-06-01	Amendment 01 Amendment 02	5/15/06	7/18/06	December 4, 2006 - Contract awarded to BioCryst Pharmaceuticals Inc. for $102.6 million. (Press Release)
Antigen Sparing Pandemic Influenza Vaccine		ORDC-VB-05-08	Modification 01 Modification 02 Modification 03 Amendment 01 Amendment 02 Pre-Proposal Conference 01 Pre-proposal Powerpoint Presentation 01 SF 30 Amendment No. 2 of Solicitation Amendment 03	3/17/06	5/2/06
Domestic Influenza Vaccine Capacity Building and Advanced Development of Recombinant Influenza Vaccines		RFI-ORDC-06-02
Acquisition of H5N1 avian influenza vaccine for the Strategic National Stockpile	ORDC-VB-05-13	July 13, 2005 – RFP ORDC V&B 05-13 entitled "H5N1 Vaccine Manufacturing" issued for the manufacturing of H5N1 vaccine at commercial scale using licensed process	Modification 01 to RFP and Amendment 02 to RFP Amendment 03 to RFP Amendment 04 to RFP Amendment 05 to RFP	7/8/05	7/29/05	Sept. 7, 2005 - Contract (HHS# 100-2005-00004C) awarded to sanofi pasteur for $100 M to manufacture 3.33 M doses of H5N1 bulk vaccine (90 µg HA/dose) (Press Release). October 24, 2005 - Contract (HHS # 100-2005-00005I) awarded to Chiron for $63 M to manufacture 2 M doses of H5N1 bulk vaccine (90 µg HA/dose) (Press Release).
Cell and Recombinant Based Pandemic Influenza Vaccine	ORDC-VB-05-04	Apr. 28, 2005 – RFP ORDC V& B 05-04 entitled "Cell- and Recombinant-based Pandmeic Influenza Vaccine" issued to fund more contracts to facilitate the advance development of cell-based influenza vaccine towards U.S. licensure in domestic manufacturing facilities.	Amendment 01 to RFP Amendment 02 to RFP Amendment 03 to RFP Amendment 04 to RFP Pre-Proposal Conference Presentation 01 Breakdown of Proposed Costs 01	4/29/2005	6/21/2005	May 4, 2006 - 5 Contracts awarded to vaccine manufacturers totaling $1.004 billion: GlaxoSmithKline ($274.75 M), MedImmune ($169.46 M), Novartis Vaccines and Diagnostics ($220.15 M), DynPort Vaccine ($40.97 M), and Solvay Pharmaceuticals ($298.59 M). (Press Release)
Improved Process Manufacturing	ORDC-VB-05-07		Modification 01 to Synopsis Modification 02 to Synopsis Modificaiton 03 to Synopsis	3/17/05
Influenza IND Vaccine 2004-2005 Season ***		RFP 2005-B-00355		11/04/04	11/10/04	February 1, 2005 - Contract No. 200200511360 entitled "IND seasonal Influenza Vaccine" was awarded to Berna Biotech of Bern, Switzerland at a cost of $1.75 M December 10, 2004 - Contract No. 200200510939 entitled "IND seasonal Influenza Vaccine" was awarded to Glaxo SmithKline of Philadelphia, PA at a cost of $8.68 M (Press release)
Avian Influenza H5N1 Vaccine **		Letter RFP 2004-N-01346		5/14/04	6/25/04	August 31, 2004 – Contract No. 200200409881 entitled “Avian Influenza H5N1 Vaccine” was awarded to sanofi pasteur (formerly Aventis Pasteur US, Inc.) of Swiftwater, PA at a cost of $12.96 M for the base contract (Press Release)
Q Egg-based Pandemic Influenza Vaccine **		RFP 2004-N-01101A	Amendment 01 to RFP Amendment 02 to RFP Amendment 03 to RFP Amendment 04 to RFP	2/19/04	3/30/04	September 30, 2004 to Sanofi Aventis, Inc. (Press Release) September 30, 2004 - Contract No. 200200410431 entitled "Egg-based Pandemic Influenza Vaccine" was awarded to sanofi pasteur of Swiftwater, PA at a cost of $40.1 M
Cell-based Pandemic Influenza Vaccine **		RFP 2004-N-01102	Amendment 01 to RFP Modification 01 to RFP Amendment 02 to RFP Amendment 03 to RFP	2/18/04	4/14/04	April 1, 2005 - Contract No. 200200511758 entitled "Cell-based Pandemic Influenza Vaccine" was awarded to Sanofi Pasteur of Lyon, France at a cost of $97.1M (Press Release)

*ORDC is also involved in other public health and emergency preparedness procurements. Project BioShield dollars will not be used for these procurements.

** Contracts administered in collaboration with HHS' National Vaccine Program Office and the Programs and Grants Office of the Center for Disease Control and Prevention.

*** Contracts administered in collaboration with the Centers for Disease Control and Prevention.